WO1996017675A2 - Method of treating membranes - Google Patents
Method of treating membranes Download PDFInfo
- Publication number
- WO1996017675A2 WO1996017675A2 PCT/GB1995/002829 GB9502829W WO9617675A2 WO 1996017675 A2 WO1996017675 A2 WO 1996017675A2 GB 9502829 W GB9502829 W GB 9502829W WO 9617675 A2 WO9617675 A2 WO 9617675A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- adhesive
- blocking moiety
- coating
- blocking
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 216
- 238000000034 method Methods 0.000 title claims abstract description 45
- 239000000853 adhesive Substances 0.000 claims abstract description 71
- 230000001070 adhesive effect Effects 0.000 claims abstract description 71
- 230000000903 blocking effect Effects 0.000 claims abstract description 37
- 238000000576 coating method Methods 0.000 claims abstract description 35
- 239000011248 coating agent Substances 0.000 claims abstract description 31
- 239000012530 fluid Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 102000004190 Enzymes Human genes 0.000 claims abstract description 9
- 108090000790 Enzymes Proteins 0.000 claims abstract description 9
- 102000004856 Lectins Human genes 0.000 claims abstract description 5
- 108090001090 Lectins Proteins 0.000 claims abstract description 5
- 239000002523 lectin Substances 0.000 claims abstract description 5
- 235000000346 sugar Nutrition 0.000 claims abstract description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 3
- 239000000194 fatty acid Substances 0.000 claims abstract description 3
- 229930195729 fatty acid Natural products 0.000 claims abstract description 3
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 3
- 238000001035 drying Methods 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000014171 Milk Proteins Human genes 0.000 claims description 2
- 108010011756 Milk Proteins Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 235000021239 milk protein Nutrition 0.000 claims description 2
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 238000003780 insertion Methods 0.000 abstract description 3
- 230000037431 insertion Effects 0.000 abstract description 3
- 150000003384 small molecules Chemical class 0.000 abstract description 3
- 150000008163 sugars Chemical class 0.000 abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 2
- 239000000835 fiber Substances 0.000 description 39
- 239000000463 material Substances 0.000 description 24
- 239000003795 chemical substances by application Substances 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000012452 mother liquor Substances 0.000 description 11
- 229920002492 poly(sulfone) Polymers 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- -1 glucose Chemical class 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 5
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 5
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 238000010008 shearing Methods 0.000 description 5
- 238000009736 wetting Methods 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000002981 blocking agent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000007373 indentation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XYIPYISRNJUPBA-UHFFFAOYSA-N [3-(3'-methoxyspiro[adamantane-2,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC(C3)CC2C4)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 XYIPYISRNJUPBA-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- SMNPLAKEGAEPJD-UHFFFAOYSA-N chembl34922 Chemical compound Cl.Cl.Cl.C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C=C4N=C(NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 SMNPLAKEGAEPJD-UHFFFAOYSA-N 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 229940058401 polytetrafluoroethylene Drugs 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 241000202955 Mycoplasma bovigenitalium Species 0.000 description 1
- 241001138504 Mycoplasma bovis Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194005 Streptococcus sp. 'group G' Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/0088—Physical treatment with compounds, e.g. swelling, coating or impregnation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
- B01D63/021—Manufacturing thereof
- B01D63/022—Encapsulating hollow fibres
- B01D63/0222—Encapsulating hollow fibres using centrifugal forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D65/00—Accessories or auxiliary operations, in general, for separation processes or apparatus using semi-permeable membranes
- B01D65/003—Membrane bonding or sealing
Definitions
- the present invention is concerned with a process for producing sealed units which comprise a membrane.
- Sealed membrane units are desirable for many purposes which require a filtration step.
- the membrane is sealed into the unit in such a way that the mother liquor (liquid to be processed) is separated from the filtrate by the membrane.
- the membrane unit is to be used for medical purposes, for example dialysis, it is of course particularly important for the unit to be sealed completely and for the membrane to be clean, preferably sterile.
- sealed membrane units of this type are formed using a one-part (generally tubular) outer casing.
- the membrane fibres are threaded through the outer casing and the ends of the membrane are then fixed in place by adhesive.
- the adhesive is introduced into the outer casing and the whole unit is spun, so that the centrifugal forces created cause adhesive to locate at each end of the outer casing.
- the adhesive is then allowed to set. This process has the disadvantage that an adequate seal at each end of the unit cannot be guaranteed and therefore careful testing of each unit is required.
- the ends of the hollow fibre membranes frequently become blocked by adhesive during the spinning process.
- a sealed membrane unit by using two outer casing portions.
- the membrane is located within the casing portions which are then sealed together, for example with adhesive.
- Figs 1 to 3 illustrate this method of manufacture which is described in more detail in PCT/GB95/01836.
- a quick-setting adhesive is injected into the casing close to each end of the membrane, for example a membrane fibre bundle.
- a bundle of membrane fibres may be placed into a mould and plugs of adhesive formed around each end, before transfer to an outer casing.
- each end of the membrane unit provides a seal around the edge or end of the membrane.
- the adhesive is cured by exposure to UV light.
- the exterior of each plug may be trimmed, for example by use of a sharp knife or guillotine. The cut made may also slice through the membrane ensuring that, where hollow fibre membranes are used, the exposed end of each membrane fibre is free from cured adhesive.
- setting or curing of adhesive causes the membrane material to experience shearing forces. Under certain circumstances the shearing forces can induce a tear within the membrane material.
- wetting the membrane is a simple way of introducing small molecules (the molecules of which the liquid is comprised) into the interstices of the membrane material.
- the small molecules are believed to partially occlude the spaces present in the structure of the membrane material and prevents the adhesive from penetrating deeply.
- the membrane itself is not saturated with adhesive it is less affected during the curing process by the chemical and physical alterations that occur in the adhesive composition during curing.
- the membrane In a development of the invention it was then found that it is not essential for the membrane to be physically wet; it is necessary only for penetration of the adhesive (or any similar material coating the membrane) into the interstices of the membrane material to be hindered, preferably substantially prevented. Thus, the undesirable shearing forces experienced when adhesive is applied directly to the membrane and then cured may be avoided if the membrane has been pre- treated with a blocking moiety.
- the blocking moiety can be used to localise a coating onto one surface of the membrane, rather than simply applying the coating moiety and allowing it to penetrate through the membrane, and possibly even being lost from the membrane. This avoids the stresses on the membrane due to drying of the coating. Moreover the coating can be selected to alter the characteristics of the membrane.
- the present invention provides a method of treating at least a portion of a membrane, said method comprising the following steps:
- step b applying a coating to said surface of the treated membrane portion of step a) .
- blocking moiety should normally be sufficient to at least partially hinder entry of the coating into the interstices of the membrane portion.
- the blocking moiety may be generated on a surface of the membrane or within the porous structure of the membrane by chemical reaction.
- the invention also includes coated membranes produced as described above.
- the present invention provides a method of forming a (preferably sealed) membrane unit wherein a portion of the membrane is coated, said method comprising the step of pre-treating said membrane portion to be coated with a blocking moiety.
- coated includes membranes coated with adhesive for fixing purposes, the adhesive being applied to a relatively small area of membrane to form a thick layer or "plug". More conventional coatings which cover substantially all of the membrane surface relatively thinly are also included within the term "coated”.
- the part of the membrane to be coated may be wet.
- the blocking moiety is a solid
- it may be applied to the membrane in dissolved, colloidal or suspended form together with a delivery fluid.
- the coating may be applied whilst the membrane surface is still wet from the delivery fluid or alternatively the membrane may be allowed to dry before application of the coating.
- the blocking protein is formed by precipitation in the interstices of the membrane when two separate fluids are allowed to flow down separate sides of the membrane; precipitation occurring when the two fluids come into contact with each other following migration through the membrane.
- blocking moieties include liquids (ie the membrane is wet when the adhesive is applied) and also small inorganic or organic molecules. Particular mention may be made of amino acids, peptides, proteins, sugars, fatty acids, and mixtures including these molecules.
- Serum albumins for example bovine serum albumin and human serum albumen, are suitable as blocking proteins.
- milk proteins such as caseins.
- Sugars include monosaccharides such as glucose, di-saccharides such as fructose, galactose etc and polysaccharides such as starches, cellulose, hemi-cellulose and the like. The size of the blocking moiety should of course be such to enable entry into the interstices of the membrane material. Generally, therefore the physical characteristics of the membrane will need to be considered when selecting a suitable blocking moiety.
- coatings which may be applied to a membrane pre- treated according to the present invention include (but are not limited to) enzymes (such as hydrogen peroxidose, glucose oxidose etc) , antibodies, lectins, epitopes, reactive groups (eg carboxyl groups, epoxides, amine groups) and the like.
- enzymes such as hydrogen peroxidose, glucose oxidose etc
- antibodies such as lectins, epitopes
- reactive groups eg carboxyl groups, epoxides, amine groups
- the coated membrane may be incorporated into a membrane filter unit as described and illustrated in PCT/GB95/01834.
- the coating applied may be used to determine the presence of a component of the mother liquor as described therein.
- the present invention provides a method of forming a membrane unit wherein a part of the membrane is in contact with adhesive, said method comprising the step of wetting at least a portion of the part of said membrane prior to setting or curing of the adhesive.
- the present invention provides a method of forming a membrane unit wherein the membrane is in contact with a set or cured adhesive, said method being characterised in that the adhesive setting or curing step is carried out whilst an area of membrane in contact with the adhesive is wet.
- the blocking moiety is a fluid
- the whole surface area of the membrane may be wet.
- the membrane may be wet before insertion into the membrane unit casing, for example as in the case of the formation of membrane fibre bundles held at each end by an adhesive plug.
- the membrane may be wet after insertion into the membrane unit casing.
- the membrane may be wet before or after introduction of the coating.
- the membrane is generally wet before the coating is inserted either into the membrane unit or into the mould.
- the coating is an adhesive it may be introduced as a mixture with a suitable wetting fluid.
- the membrane may be wet with any fluid and mention may be made of water or other aqueous systems, including buffers (for example Tween) .
- Organic fluids such as for example ethanol, isopropanol, acetone, dichloroethane or mixtures containing them
- the membrane may be wet by dipping or soaking in fluid or by the deliberate introduction of the fluid into or onto the membrane, for example using a syringe to inject fluid down the lumen of the membrane.
- the fluid selected to wet the membrane prior to curing of the adhesive may be part of a pre-treatment process of the membrane, for example a process coating the membrane.
- the membrane material may be any suitable membrane, and selection of the membrane will depend upon the intended end use of the filter unit.
- suitable membrane materials include polysulfone, cellulose, cellulose diacetate, polypropylene and/or ceramics materials.
- Nylon, cellulose nitrate, polytetrafluoro- ethylene (PTFE) , polyvinylidene difluoride (PVDF) and glass fibres are also suitable membranes.
- the adhesive used in the process may be any adhesive material which does not react with the membrane or outer casing materials in a dileterious manner.
- the adhesive material is quick- setting, ie cures within minutes, for example under five minutes.
- adhesive material which cures on exposure to light is particularly desirable.
- Suitable adhesive material is commercially available and mention may be made of polymers available from Ablestick Ltd (for example LCM 32, LCM 34 LCM 35), Bostick Ltd or Dynax Inc (eg 191M) as being suitable curing adhesives.
- treatment of the membrane in accordance with the invention is preferably carried out under clean, preferably sterile, conditions, for example using sterilised water as the blocking moiety.
- the membrane used is a single hollow fibre (for example a hollow fibre having an external diameter of under 1.5mm, for example 500 ⁇ m or less, such as 300 ⁇ m or less)
- curing of the adhesive is sufficient to dry the fibre.
- a further drying step may be required. Additional drying may either take place by allowing the membrane to dry naturally in the atmosphere, or by application of heat or warm air. Again, if the membrane unit is for medical or pharmaceutical use any drying should be carried out under clean, preferably sterile, conditions.
- the present invention provides a method of treating a membrane, said method comprising the following steps:
- the present invention provides a method of forming a membrane unit, said method comprising the following steps: a. exposing at least a part of the membrane area which is to be in contact with adhesive to a blocking moiety;
- filter units which may comprise a membrane treated as described above are shown in Figs 1-8.
- Figs 1 to 3 show exploded views of membrane filter units in which the membrane is treated accorded to the invention to avoid shear during setting of the adhesive;
- Figs 4 to 8 show filter units which may comprise a membrane treated according to the invention.
- FIG. 1 shows general detail of the construction of a filter unit having a casing constructed from two portions. Moulded casing halves 9 and 10 are sealed together with a UV-activated acrylic sealant to enclose a hollow fibre bundle membrane unit 11.
- the membrane unit 11 is bonded to the outer casing in such a way that a seal is formed at the ends of the whole filter cell.
- To form membrane unit 11 the bundle of membranes is pretreated by wetting with water or a buffer solution. The pretreated membrane is then placed into a mould, into which adhesive is inserted. The adhesive is then cured. The presence of the blocking agent on the membranes ensures that the membranes are not sheared during the curing of the adhesive.
- Figure 2 shows a unit having a coated membrane according to the present invention.
- the unit illustrated has outer casing portions 1, 2 and 2 ' .
- Upper outer casing portions 2 and 2 ' are alternatives allowing flexible manufacturing capacity.
- a membrane bundle 3 is manufactured with cured adhesive plugs 4, 5 at each end thereof as described above for Fig. 1.
- the plugs 4 , 5 have been trimmed at their outer edges so that the end of each hollow membrane fibre is fully exposed.
- the adhesive plugs 4, 5 fit snugly into corresponding indentations 6 in the outer casing portions 1, 2, 2'.
- To seal the unit adhesive is smeared onto lip 7 of either or both upper and lower outer casing portions. Curing of this adhesive does not create stress in the treated membrane fibres.
- indentations 6 may also receive adhesive.
- the membrane bundle 3 is located in the outer casing portions so that the plugs 4, 5 are both correctly located in indentations 6.
- the outer casing portions 1 and 2 (or 1 and 2' as appropriate) are then aligned and held together whilst the adhesive sets firmly.
- the unit is shaped so that a tight seal around each plug 4, 5 is produced.
- Inlet and outlet ports 8, 9 are also illustrated and optionally connectors may be adfixed thereto.
- side ports 10 are also shown; these enable sampling of the mother liquor during the process or addition of a second fluid to the mother liquor, for example to control the trans-membrane pressure.
- the side ports may be used to hold a sensor which monitors the filtration process.
- FIG 3 illustrates an alternative unit which comprises a membrane bundle treated according to the present invention.
- This unit is formed as described for the unit of Figure 2 but the membrane bundle is bent into a "U"-shape to fit into the outer casing portions.
- FIG. 4 shows a filter unit device indicated generally at 100 having a flat sheet membrane filter 12 which separates the flow-through cell 13 from the filtrate chamber 14.
- the membrane may be treated according to the invention on one or both surfaces.
- liquor is pumped at pressure through the cell in the direction shown by the arrow and the filtrate may leave the filtrate chamber 14 by a port 15 which may be fitted with a tap (not shown) .
- a further fluid may be input via port 15 and be filtered across membrane 12.
- a reactive or binding agent may be located on the membrane filter 12, cell 13 and/or in chamber 14.
- the blocking moiety and, subsequently, the coating may be sequentially introduced into a device (eg as illustrated in Fig. 4) having an untreated membrane.
- the membrane may be treated in situ when part of the device. This may allow easier handling of the membrane.
- Figure 5 illustrates a device similar to that shown in Figure 4 and described above.
- the filter membrane 12 is in the form of a tube 16.
- Either the internal or external surfaces (or both) of the hollow fibre membrane may be treated as described for the present invention.
- the blocking agent used may be a sugar solution, which is then followed by an antibody or lectin coating.
- the mother liquor is passed through the lumen of tube 16 (which forms flow-through cell 13) , preferably at a controlled pressure, in the direction of the arrow.
- the filtrate will collect in chamber 14 and may be taken off via port 15 which again may if desired be fitted with a tap.
- port 15 may be used to input a second fluid, either to react with the filtrate of the mother liquor (ie the agent may be present in the second fluid) or to control the pressure within the device. Reaction of the coating on the membrane with a component of the mother liquor may result in a detectable change, for example in fluorescene or other photometric change.
- FIG. 6 illustrates a further embodiment, similar to those previously described with respect to Figures 4 and 5.
- the membrane filter (shown generally at 12) is in the form of hollow fibre membranes 17 of which two are illustrated for simplicity.
- the number of hollow fibre membranes may be adjusted from 1 to several hundred depending upon the size of the device.
- Each or any of the hollow fibre membranes may be coated.
- the coatings used may be the same, or may vary.
- the blocking moieties required may be varied as required.
- the lumen of the individual fibres are used to transport the mother liquor into the device and thus act as the flow- through cell.
- the filtrate collects in chamber 14.
- the ends of the hollow fibres are sealed into the device to prevent the mother liquor entering the filtrate chamber 14 by any means other than by passing across the membrane.
- Figure 7 depicts a further embodiment of device 100 with tubular filter membrane 12 as depicted in Figure 5 but with the addition of a direct sensor 18.
- the sensor 18 may be, for example, a pH sensor, a conductivity sensor or a biosensor.
- the sensor may detect the reaction of the component of interest with the coating on the membrane. In use the component of interest passes across the membrane filter 12 into the filtrate chamber 14. The pressure differential across the membrane may be controlled via port 15 which may contain a tap or valve.
- the component of interest may react with the coating on the membrane and then be detected by sensor 18 which then generates production of an output signal, preferably an electrical, audible or visual output signal.
- Figure 8 illustrate three further embodiments of a device having a membrane treated according to the present invention.
- the membrane 12 consists of a single hollow fibre membrane, having an internal lumen of approximately lmm.
- the membrane is coated on its outer surface.
- the whole of the volume between the exterior surface of the membrane and the interior surface of the outer casing 19 is filled with a material 110, such as LCM 32 or LCM 35 from Ablestick, which contains an agent able to react with a component of interest in the mother liquor.
- a material 110 such as LCM 32 or LCM 35 from Ablestick, which contains an agent able to react with a component of interest in the mother liquor.
- the mother liquor is passed down the lumen of the hollow fibre membrane 17 and filtrate moves across the membrane surface by cross-flow filtration.
- the component of interest present in the filtrate then encounters the agent held within the material 110.
- the material is solid and the agent is unifor ily distributed therein.
- a porous material encapsulating the agent could equally be used.
- the component may either be modified by reacting with the agent or may be simply detected by the agent which may not alter it physically or chemically.
- the agent could be light emitting, photosensitive or photoreactive.
- the material 110 does not entirely fill the volume between the exterior surface of the membrane and the interior surface of the outer casing 19, but leaves a pre-deter ined volume able to accept filtrate.
- the agent may be present either in the free volume or else be held within material 110 as described for Figure 8A above. Alternatively two different agents may be present in these separate physical locations.
- the device of Figure 8B could also be produced having two or more (for example three, four or five) volumes separately filled with material 110 (or with different types of material 110) and separated or abutting each other. Again different agents or different concentrations of agents could be contained in each.
- the device is as shown in Figure 8B, except that the device further includes a additional port 15.
- Port 15 may be used to draw off filtrate, to introduce a second fluid, optionally containing an agent to modify or detect the component of interest or simply to adjust the pressure and thus the flow across the membrane.
- a membrane in the form of a hollow fibre was taken. Before encapsulation of the membrane fibre into a sealed outer casing, the fibre was treated with a solution of buffered bovine serum albumen (BSA) . Treatment occurred by controlled flow of the buffered BSA through the lumen of the fibre with slight resistance to the flow.
- BSA buffered bovine serum albumen
- the membrane fibre was air dried under sterile conditions at ambient temperature for approximately 1% hours.
- the treated membrane fibre was placed within an outer casing and was sealed into the outer casing by application of an adhesive at each end of the membrane fibre. Upon curing of the adhesive using UV light no tear in the fibre was observed.
- a buffered enzyme solution was pushed through the lumen of the membrane fibre using a syringe.
- the enzyme adhered to the inner surface of the membrane and excess enzyme was washed off with buffer.
- a substrate of the enzyme was introduced into the lumen of the membrane fibre and the enzymic reaction was observed optically. It was noted that only the inner surface of the membrane fibre had been coated with enzyme.
- the immunoassay reader detected chemiluminescence by a photon counter which was developed by A.D.L Ltd, and was used for these experiments.
- Filter Unit The filers used were 5mm FSM Technologies Ltd GlowgrubTM hollow fibre membrane filter units. These units comprise a single hollow fibre membrane having a diameter of approximately 280 ⁇ m up to 1mm outer diameter pre- blocked in blocking buffer, and potted at either end with adhesive so that the volume described by the outer surface of the fibre and the inner surface of the casing is completely enclosed. The lumen of the hollow fibre is not blocked by the adhesive and the sample flows along the lumen of the fibre and undergoes cross-flow filtration, the filtrate collecting in the volume between the outer fibre surface and inner wall of the casing. Details of the blocking buffer are given at Item 6 below.
- Antigen A formalin fixed culture of virulent Staphylococcus aureus at a concentration of 10 7 cellsml "1 supplied by FAS Medical Ltd.
- the wash buffer and antibody diulation buffer was 20mM Tris pH 8.0 with 0.05% (v/v) Tween 20 and 0.5% v/v Casein/Maleic acid buffer.
- the buffers were freshly prepared and sterilised by autoclaving.
- the blocking buffer used to pretreat the membranes was 20mM Tris pH 8.0 with 0.05% (v/v) Tween 20 and 1.0% (v/v) Casein/Maleic Acid.
- Substrate Disodium 3-(4-methoxyspiro ⁇ l,2- dioxetans-3,2'-tricyclo[3.3.1.l 37 ]decan ⁇ -4- yl)phenyl phosphate (AMPPD) is a non-isotopic, stable substrate which can detect 4.Opg enzyme after 5 min reaction time.
- the substrate used was a pre-prepared working strength solution in DEA buffer at pH 10.0.
- the filter unit was fitted into a holder with a 75% restrictor and Luer fitment. 1 ml of antigen solution was passed through. This was followed with approximately 500 ⁇ 1° Ab, the filter unit was laid aside for 1 min to allow antigen/antibody interaction then 500 ⁇ l of 2° Ab applied. The filter unit was laid aside for a further minute after which time it was washed with 1ml wash buffer. This was repeated minus antigen for the negative control. When all filter units had been treated each in turn received 500 ⁇ l AMPPD at timed intervals. A count was made after 5 min reaction time.
- RLU Relative light units, being the relative difference in light emitted due to the presence of the filter unit, compared to the background reading of the instrument alone.
- Non-specific binding has caused significant problems and multiplied the wash steps by many times with other systems.
- test over control readings indicate a significant increase in count. Even with high debris high turbidity samples a 30% increase over background is normal.
- Polypropylene hollow fibre membranes were obtained and the lumen washed with Tween buffer as blocking agent, by injecting the Tween buffer down the lumen using a syringe.
- concentration of the Tween buffer will be selected in accordance with the characteristics of the membrane, but generally a concentration of 0.01% to 1.0% (v/v) is sufficient.
- the membrane was then dried by hot air in a drying oven. The treated membrane was immersed in a solution of acridine orange and dried in a hot air oven.
- the coated membrane was inserted and sealed into a membrane unit and then challenged with a sample containing bacteria, the sample being introduced down the lumen of the membrane. A UV response was observed from the acridine orange coated membrane, indicating that bacteria had been detected in the sample.
- the outer surface of the hollow fibre membrane can likewise be treated as described above. Where only the outer surface is to be treated, the blocking agent and/or the coating may be sprayed on to the fibre surface.
- the treated membrane described above may likewise be used to detect the presence of virus in a sample, since the acridine orange coating binds to nucleic acids to give a UV detectable response.
- the Example described above may be repeated using Bisbenzimide H33258 of Hoechst to replace the acridine orange as coating. Bisbenzimide H33258 gives a fluorescent staining of DNA in cells (see Kim et al, Anal Biochem 174:168 (1988)).
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95938540A EP0796140A2 (en) | 1994-12-08 | 1995-12-05 | Method of treating membranes |
AU39899/95A AU3989995A (en) | 1994-12-08 | 1995-12-05 | Method of treating membranes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9424723.6 | 1994-12-08 | ||
GBGB9424723.6A GB9424723D0 (en) | 1994-12-08 | 1994-12-08 | Method |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996017675A2 true WO1996017675A2 (en) | 1996-06-13 |
WO1996017675A3 WO1996017675A3 (en) | 1996-12-19 |
Family
ID=10765568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1995/002829 WO1996017675A2 (en) | 1994-12-08 | 1995-12-05 | Method of treating membranes |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0796140A2 (en) |
AU (1) | AU3989995A (en) |
GB (1) | GB9424723D0 (en) |
WO (1) | WO1996017675A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0923955A2 (en) * | 1997-12-17 | 1999-06-23 | Terumo Kabushiki Kaisha | Manufacturing method of artificial organ, hollow fiber membrane, and dialyzer of hollow fiber membrane type |
WO2013138170A1 (en) * | 2012-03-15 | 2013-09-19 | Koch Membrane Systems, Inc. | Method for sealing hollow fiber membranes |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB212233A (en) * | 1923-02-27 | 1924-04-03 | Eugene Hyacinthe Fouard | |
US3648845A (en) * | 1969-09-02 | 1972-03-14 | Us Interior | Thin film separation membranes and processes for making same |
GB1357347A (en) * | 1970-11-30 | 1974-06-19 | Secretary Trade Ind Brit | Permeable membranes |
US4389363A (en) * | 1980-11-03 | 1983-06-21 | Baxter Travenol Laboratories, Inc. | Method of potting microporous hollow fiber bundles |
WO1986005117A1 (en) * | 1985-03-06 | 1986-09-12 | Memtec Limited | Altering pore size distributions |
EP0245863A2 (en) * | 1986-05-16 | 1987-11-19 | Millipore Corporation | Composite ultrafiltration membranes |
EP0288380A1 (en) * | 1987-04-23 | 1988-10-26 | Commissariat A L'energie Atomique | Semi-permeable organo-mineral membrane, and processes for its preparation |
EP0338774A2 (en) * | 1988-04-22 | 1989-10-25 | Japan Gore-Tex, Inc. | Method for fastening soft porous tubes |
US4879032A (en) * | 1984-06-04 | 1989-11-07 | Allied Resin Corporation | Fluid separatory devices having improved potting and adhesive compositions |
WO1993003693A1 (en) * | 1991-08-23 | 1993-03-04 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59112805A (en) * | 1982-12-20 | 1984-06-29 | Nitto Electric Ind Co Ltd | Preparation of liquid separation apparatus |
JPS63107707A (en) * | 1986-10-27 | 1988-05-12 | Fuji Photo Film Co Ltd | Manufacture of filter cartridge |
JPS6447418A (en) * | 1987-05-29 | 1989-02-21 | Sekisui Chemical Co Ltd | Filter and its production |
-
1994
- 1994-12-08 GB GBGB9424723.6A patent/GB9424723D0/en active Pending
-
1995
- 1995-12-05 EP EP95938540A patent/EP0796140A2/en not_active Withdrawn
- 1995-12-05 AU AU39899/95A patent/AU3989995A/en not_active Abandoned
- 1995-12-05 WO PCT/GB1995/002829 patent/WO1996017675A2/en not_active Application Discontinuation
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB212233A (en) * | 1923-02-27 | 1924-04-03 | Eugene Hyacinthe Fouard | |
US3648845A (en) * | 1969-09-02 | 1972-03-14 | Us Interior | Thin film separation membranes and processes for making same |
GB1357347A (en) * | 1970-11-30 | 1974-06-19 | Secretary Trade Ind Brit | Permeable membranes |
US4389363A (en) * | 1980-11-03 | 1983-06-21 | Baxter Travenol Laboratories, Inc. | Method of potting microporous hollow fiber bundles |
US4879032A (en) * | 1984-06-04 | 1989-11-07 | Allied Resin Corporation | Fluid separatory devices having improved potting and adhesive compositions |
WO1986005117A1 (en) * | 1985-03-06 | 1986-09-12 | Memtec Limited | Altering pore size distributions |
EP0245863A2 (en) * | 1986-05-16 | 1987-11-19 | Millipore Corporation | Composite ultrafiltration membranes |
EP0288380A1 (en) * | 1987-04-23 | 1988-10-26 | Commissariat A L'energie Atomique | Semi-permeable organo-mineral membrane, and processes for its preparation |
EP0338774A2 (en) * | 1988-04-22 | 1989-10-25 | Japan Gore-Tex, Inc. | Method for fastening soft porous tubes |
WO1993003693A1 (en) * | 1991-08-23 | 1993-03-04 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset |
Non-Patent Citations (3)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 12, no. 349 (C-529) [3196] , 20 September 1988 & JP,A,63 107707 (FUJI PHOTO FILM CO LTD), 12 May 1988, * |
PATENT ABSTRACTS OF JAPAN vol. 13, no. 238 (C-603), 5 June 1989 & JP,A,01 047418 (SEKISUI CHEM CO LTD), 21 February 1989, & DATABASE WPI Section Ch, Week 8913 Derwent Publications Ltd., London, GB; Class J01, AN 89-098055 & CHEMICAL ABSTRACTS, vol. 112, no. 17, 23 April 1990 Columbus, Ohio, US; abstract no. 154813, * |
PATENT ABSTRACTS OF JAPAN vol. 8, no. 225 (C-247), 16 October 1984 & JP,A,59 112805 (NITTO DENKI KKK), 29 June 1984, & CHEMICAL ABSTRACTS, vol. 101, no. 22, 26 November 1984 Columbus, Ohio, US; abstract no. 194233, & DATABASE WPI Section Ch, Week 8432 Derwent Publications Ltd., London, GB; Class A35, AN 84-198046 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0923955A2 (en) * | 1997-12-17 | 1999-06-23 | Terumo Kabushiki Kaisha | Manufacturing method of artificial organ, hollow fiber membrane, and dialyzer of hollow fiber membrane type |
EP0923955A3 (en) * | 1997-12-17 | 1999-12-15 | Terumo Kabushiki Kaisha | Manufacturing method of artificial organ, hollow fiber membrane, and dialyzer of hollow fiber membrane type |
US6478960B1 (en) * | 1997-12-17 | 2002-11-12 | Asahi Medical Co., Ltd. | Manufacturing method of artificial organ, hollow fiber, and dialyzer of hollow fiber membrane type |
WO2013138170A1 (en) * | 2012-03-15 | 2013-09-19 | Koch Membrane Systems, Inc. | Method for sealing hollow fiber membranes |
US9498753B2 (en) | 2012-03-15 | 2016-11-22 | Koch Membrane Systems, Inc. | Method for sealing hollow fiber membranes |
US9968888B2 (en) | 2012-03-15 | 2018-05-15 | Koch Membrane Systems, Inc. | Method for sealing hollow fiber membranes |
Also Published As
Publication number | Publication date |
---|---|
EP0796140A2 (en) | 1997-09-24 |
AU3989995A (en) | 1996-06-26 |
WO1996017675A3 (en) | 1996-12-19 |
GB9424723D0 (en) | 1995-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8956880B2 (en) | Detection of micro-organisms | |
US4797259A (en) | Well-type diagnostic plate device | |
EP0037394B1 (en) | A device for removal of substances from a liquid | |
CN101002095B (en) | Chromatographic detection apparatus, method of testing and kit utilizing the same | |
ES2268706T3 (en) | DEVICES AND PROCEDURES FOR SEPARATING BLOOD CELL COMPONENTS FROM THE BLOOD LIQUID PORTION. | |
AU2012203289B2 (en) | Plasma separation | |
CA2553234C (en) | Fractionator and method of fractionation | |
SE527036C2 (en) | Controlled flow analysis device and corresponding procedure | |
WO2002008727A1 (en) | Reagent delivery device and method of use | |
EP0133700A2 (en) | Improved multilayered test device for detecting analytes in liquid test samples | |
CN103649759A (en) | Microfluidic devices and methods of manufacture and use | |
EP0943094A2 (en) | Sensor laminates and multi-sectioned fluid delivery devices for detecting by immunoassay target molecules in biological fluids | |
JPH03205563A (en) | Device and method for separating plasma or serum from whole blood | |
CN104081209A (en) | Method and device for assaying an antigen present on erythrocytes or an antibody binding to an antigen present on erythrocytes | |
CN110292959B (en) | Microfluidic chip and preparation method and application thereof | |
EP3971574A1 (en) | Functionalized biological multilayer porous membrane immune carrier, preparation method, and application | |
EP2167967A2 (en) | Device and method for identifying and determining blood groups | |
WO1996017675A2 (en) | Method of treating membranes | |
US10690652B2 (en) | Method for detecting sickle-cell disease and kit for implementing same | |
JP6048650B2 (en) | Membrane support for detecting sugar chain recognition molecules | |
JPH0245064A (en) | Device for removing interleukin 2 receptor and blood extra-corporeal circulating device provided with this device | |
FR2709349A1 (en) | A method of identifying an immunological substance using a multimembrane system | |
JP2022153079A (en) | Method and kit for detecting bacteria in blood and urine from urine specimen | |
CN109608679A (en) | A kind of bionical membrane preparation method of nuclear pore complex graft polymers | |
Ballerini et al. | Thread as a Low-Cost Biodiagnostic Substrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 860040 Date of ref document: 19970609 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995938540 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995938540 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995938540 Country of ref document: EP |